Clinical Coagulation, Malmö
1 – 20 of 628
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B) : 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
2024) In The Lancet Haematology(
- Contribution to journal › Article
-
Mark
SERPINH1 variants and thrombotic risk among middle-aged and older adults : a population-based cohort study
(
- Contribution to journal › Letter
-
Mark
Haemophilia A - In pursuit of optimised outcomes via personalised treatment
2024) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
- 2023
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
-
Mark
Association of Circulating Long Noncoding 7S RNA with Deep Vein Thrombosis
(
- Contribution to journal › Article
-
Mark
Validation of immunofluorescence analysis of blood smears in patients with inherited platelet disorders
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in development
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Acquired Haemophilia A in four north European countries : survey of 181 patients
(
- Contribution to journal › Article
-
Mark
Real-world prophylactic usage of recombinant factor IX Fc in Sweden : A report from the Swedish National Registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B : post hoc analysis of phase III trials using patient-reported outcomes
(
- Contribution to journal › Article
-
Mark
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice
(
- Contribution to journal › Article
-
Mark
Novel methodology for the evaluation of symptoms reported by patients with newly diagnosed atrial fibrillation : Application of natural language processing to electronic medical records data
(
- Contribution to journal › Article
-
Mark
A need to increase von Willebrand disease awareness : vwdtest.com – A global initiative to help address this gap
(
- Contribution to journal › Scientific review
-
Mark
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
(
- Contribution to journal › Article
-
Mark
Haemophilia B - Diagnostic Insights, Genetic Aspects and Clinical Outcomes
2023) In Lund University, Faculty of Medicine, Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
(
- Contribution to journal › Scientific review
-
Mark
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia : A review of the literature
(
- Contribution to journal › Scientific review